A novel human pain insensitivity disorder caused by a point mutation in ZFHX2.

Chronic pain is a major global public health issue causing a severe impact on both the quality of life for sufferers and the wider economy. Despite the significant clinical burden, little progress has been made in terms of therapeutic development. A unique approach to identifying new human-validated analgesic drug targets is to study rare families with inherited pain insensitivity. Here we have analysed an otherwise normal family where six affected individuals display a pain insensitive phenotype that is characterized by hyposensitivity to noxious heat and painless bone fractures. This autosomal dominant disorder is found in three generations and is not associated with a peripheral neuropathy. A novel point mutation in ZFHX2, encoding a putative transcription factor expressed in small diameter sensory neurons, was identified by whole exome sequencing that segregates with the pain insensitivity. The mutation is predicted to change an evolutionarily highly conserved arginine residue 1913 to a lysine within a homeodomain. Bacterial artificial chromosome (BAC) transgenic mice bearing the orthologous murine p.R1907K mutation, as well as Zfhx2 null mutant mice, have significant deficits in pain sensitivity. Gene expression analyses in dorsal root ganglia from mutant and wild-type mice show altered expression of genes implicated in peripheral pain mechanisms. The ZFHX2 variant and downstream regulated genes associated with a human pain-insensitive phenotype are therefore potential novel targets for the development of new analgesic drugs.awx326media15680039660001.

Behavioral abnormalities observed in Zfhx2-deficient mice.

Zfhx2 (also known as zfh-5) encodes a transcription factor containing three homeobox domains and 18 Zn-finger motifs. We have reported that Zfhx2 mRNA is expressed mainly in differentiating neurons in the mouse brain and its expression level is negatively regulated by the antisense transcripts of Zfhx2. Although the expression profile of Zfhx2 suggests that ZFHX2 might have a role in a particular step of neuronal differentiation, the specific function of the gene has not been determined. We generated a Zfhx2-deficient mouse line and performed a comprehensive battery of behavioral tests to elucidate the function of ZFHX2. Homozygous Zfhx2-deficient mice showed several behavioral abnormalities, namely, hyperactivity, enhanced depression-like behaviors, and an aberrantly altered anxiety-like phenotype. These behavioral phenotypes suggest that ZFHX2 might play roles in controlling emotional aspects through the function of monoaminergic neurons where ZFHX2 is expressed. Moreover, considering their phenotypes, the Zfhx2-deficient mice may provide a novel model of human psychiatric disorders.

Novel transcription factor zfh-5 is negatively regulated by its own antisense RNA in mouse brain.

Here, we report features of a novel transcription factor zfh-5, which we isolated from the mouse brain; in addition to the mRNA, the antisense strand of zfh-5 is also expressed in the developing brain, in a manner complementary to the expression of zfh-5 mRNA. Although most neurons express zfh-5 mRNA soon after their final mitosis, several types of neurons, such as the pyramidal and granule cells in the hippocampus, express the zfh-5 antisense RNA prior to the mRNA expression. Using gene-targeting approach, we showed that this antisense RNA has a negative regulatory role on the expression of zfh-5 mRNA. These observations suggest that, in specific types of neurons, the expression of zfh-5 is additionally regulated by a mechanism depending on this antisense RNA.